177 related articles for article (PubMed ID: 35223380)
1. Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability
Perera RH; Abenojar E; Nittayacharn P; Wang X; Ramamurthy G; Peiris P; Bederman I; Basilion JP; Exner AA
Nanotheranostics; 2022; 6(3):270-285. PubMed ID: 35223380
[TBL] [Abstract][Full Text] [Related]
2. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
[TBL] [Abstract][Full Text] [Related]
3. Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
Wang Y; Lan M; Shen D; Fang K; Zhu L; Liu Y; Hao L; Li P
Int J Nanomedicine; 2020; 15():4289-4309. PubMed ID: 32606678
[TBL] [Abstract][Full Text] [Related]
4. Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.
Perera RH; de Leon A; Wang X; Wang Y; Ramamurthy G; Peiris P; Abenojar E; Basilion JP; Exner AA
Nanomedicine; 2020 Aug; 28():102213. PubMed ID: 32348874
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner AA
bioRxiv; 2023 Sep; ():. PubMed ID: 37745586
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents.
Johansen ML; Perera R; Abenojar E; Wang X; Vincent J; Exner AA; Brady-Kalnay SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671448
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.
Chen C; Perera R; Kolios MC; Wijkstra H; Mischi M; Exner AA; Turco S
Med Phys; 2022 Oct; 49(10):6547-6559. PubMed ID: 36049109
[TBL] [Abstract][Full Text] [Related]
9. Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon.
Chen C; Perera R; Mischi M; Kolios M; Exner A; Turco S
Mol Imaging Biol; 2024 Apr; 26(2):253-263. PubMed ID: 38151581
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
[TBL] [Abstract][Full Text] [Related]
12. Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer.
Zhu Y; Sun Y; Liu W; Guan W; Liu H; Duan Y; Chen Y
Nanomedicine (Lond); 2020 Dec; 15(30):2901-2916. PubMed ID: 33300812
[No Abstract] [Full Text] [Related]
13. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents.
Gao Y; Hernandez C; Yuan HX; Lilly J; Kota P; Zhou H; Wu H; Exner AA
Nanomedicine; 2017 Oct; 13(7):2159-2168. PubMed ID: 28603079
[TBL] [Abstract][Full Text] [Related]
14. Novel dual-mode nanobubbles as potential targeted contrast agents for female tumors exploration.
Yang H; Zhou T; Cai W; Yi X; Liu X; Wang Y; Zhang L; Duan Y
Tumour Biol; 2016 Oct; 37(10):14153-14163. PubMed ID: 27539728
[TBL] [Abstract][Full Text] [Related]
15. Acoustic characterization and pharmacokinetic analyses of new nanobubble ultrasound contrast agents.
Wu H; Rognin NG; Krupka TM; Solorio L; Yoshiara H; Guenette G; Sanders C; Kamiyama N; Exner AA
Ultrasound Med Biol; 2013 Nov; 39(11):2137-46. PubMed ID: 23932272
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
17. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
Wang L; Li L; Guo Y; Tong H; Fan X; Ding J; Huang H
Prostate; 2013 Aug; 73(11):1147-58. PubMed ID: 23532872
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-loaded PLGA nanobubbles for ultrasound imaging and Synergistic Targeted therapy of residual tumor during HIFU ablation.
Zhang X; Zheng Y; Wang Z; Huang S; Chen Y; Jiang W; Zhang H; Ding M; Li Q; Xiao X; Luo X; Wang Z; Qi H
Biomaterials; 2014 Jun; 35(19):5148-61. PubMed ID: 24680663
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.
Fan X; Wang L; Guo Y; Tu Z; Li L; Tong H; Xu Y; Li R; Fang K
PLoS One; 2015; 10(6):e0127419. PubMed ID: 26111008
[TBL] [Abstract][Full Text] [Related]
20. Time-intensity-curve Analysis and Tumor Extravasation of Nanobubble Ultrasound Contrast Agents.
Wu H; Abenojar EC; Perera R; De Leon AC; An T; Exner AA
Ultrasound Med Biol; 2019 Sep; 45(9):2502-2514. PubMed ID: 31248638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
